What is the current valuation of the Antiemetic Drugs Market as of 2024?

The Antiemetic Drugs Market was valued at 20.55 USD Billion in 2024. Read More

What is the projected market valuation for the Antiemetic Drugs Market in 2035?

The market is projected to reach 30.39 USD Billion by 2035. Read More

What is the expected CAGR for the Antiemetic Drugs Market during the forecast period 2025 - 2035?

The expected CAGR for the Antiemetic Drugs Market during 2025 - 2035 is 3.62%. Read More

Which therapeutic area is expected to generate the highest revenue in the Antiemetic Drugs Market?

Chemotherapy-Induced Nausea is anticipated to generate the highest revenue, with a projected valuation of 7.0 USD Billion. Read More

What are the leading companies in the Antiemetic Drugs Market?

Key players in the market include Roche, Novartis, GlaxoSmithKline, and Merck & Co. Read More

How does the market segment for oral administration compare to injectable administration?

The oral administration segment is projected to reach 12.0 USD Billion, while the injectable segment is expected to reach 9.0 USD Billion. Read More

What is the expected growth in the Neurokinin-1 Antagonists segment from 2024 to 2035?

The Neurokinin-1 Antagonists segment is expected to grow from 5.05 USD Billion in 2024 to 9.39 USD Billion by 2035. Read More

Which end user segment is projected to have the highest market share in 2035?

Hospitals are projected to have the highest market share, with an expected valuation of 12.0 USD Billion in 2035. Read More

What is the anticipated market size for the Antihistamines segment by 2035?

The Antihistamines segment is expected to reach a valuation of 4.5 USD Billion by 2035. Read More

How does the market for motion sickness treatments compare to post-operative nausea treatments?

The market for motion sickness treatments is projected to reach 6.89 USD Billion, while post-operative nausea treatments are expected to reach 6.0 USD Billion by 2035. Read More

Antiemetics Drugs Market

ID: MRFR/Pharma/41875-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Antiemetic Drugs Market Research Report By Drug Type (Serotonin Antagonists, Dopamine Antagonists, Antihistamines, Glucocorticoids, Neurokinin-1 Antagonists), By Administration Route (Oral, Injectable, Transdermal, Rectal), By Therapeutic Area (Nausea, Vomiting, Chemotherapy-Induced Nausea, Post-Operative Nausea, Motion Sickness), By End User (Hospitals, Home Care, Specialty Clinics, Ambulatory Surgical Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 Serotonin Antagonists
4.1.2 Dopamine Antagonists
4.1.3 Antihistamines
4.1.4 Glucocorticoids
4.1.5 Neurokinin-1 Antagonists
4.2 Healthcare, BY Administration Route (USD Billion)
4.2.1 Oral
4.2.2 Injectable
4.2.3 Transdermal
4.2.4 Rectal
4.3 Healthcare, BY Therapeutic Area (USD Billion)
4.3.1 Nausea
4.3.2 Vomiting
4.3.3 Chemotherapy-Induced Nausea
4.3.4 Post-Operative Nausea
4.3.5 Motion Sickness
4.4 Healthcare, BY End User (USD Billion)
4.4.1 Hospitals
4.4.2 Home Care
4.4.3 Specialty Clinics
4.4.4 Ambulatory Surgical Centers
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Roche (CH)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Novartis (CH)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 GlaxoSmithKline (GB)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Bristol-Myers Squibb (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Merck & Co. (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Teva Pharmaceutical Industries (IL)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 AstraZeneca (GB)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Sanofi (FR)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Eisai Co., Ltd. (JP)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA
6.6 US MARKET ANALYSIS BY END USER
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.9 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
6.10 CANADA MARKET ANALYSIS BY END USER
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.14 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
6.15 GERMANY MARKET ANALYSIS BY END USER
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.18 UK MARKET ANALYSIS BY THERAPEUTIC AREA
6.19 UK MARKET ANALYSIS BY END USER
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.22 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
6.23 FRANCE MARKET ANALYSIS BY END USER
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.26 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
6.27 RUSSIA MARKET ANALYSIS BY END USER
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.30 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
6.31 ITALY MARKET ANALYSIS BY END USER
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.34 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
6.35 SPAIN MARKET ANALYSIS BY END USER
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.38 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.43 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
6.44 CHINA MARKET ANALYSIS BY END USER
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.47 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
6.48 INDIA MARKET ANALYSIS BY END USER
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.51 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
6.52 JAPAN MARKET ANALYSIS BY END USER
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.55 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.59 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
6.60 MALAYSIA MARKET ANALYSIS BY END USER
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.63 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
6.64 THAILAND MARKET ANALYSIS BY END USER
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.67 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
6.68 INDONESIA MARKET ANALYSIS BY END USER
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.71 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
6.72 REST OF APAC MARKET ANALYSIS BY END USER
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.76 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
6.77 BRAZIL MARKET ANALYSIS BY END USER
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.80 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
6.81 MEXICO MARKET ANALYSIS BY END USER
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.84 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
6.85 ARGENTINA MARKET ANALYSIS BY END USER
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.93 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.97 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.101 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
6.102 REST OF MEA MARKET ANALYSIS BY END USER
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
6.114 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.2.4 BY END USER, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.3.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.3.4 BY END USER, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.4.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.4.4 BY END USER, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.5.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.5.4 BY END USER, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.6.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.6.4 BY END USER, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.7.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.7.4 BY END USER, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.8.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.8.4 BY END USER, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.9.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.9.4 BY END USER, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.10.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.10.4 BY END USER, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.11.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.11.4 BY END USER, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.12.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.12.4 BY END USER, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.13.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.13.4 BY END USER, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.14.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.14.4 BY END USER, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.15.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.15.4 BY END USER, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.16.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.16.4 BY END USER, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.17.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.17.4 BY END USER, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.18.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.18.4 BY END USER, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.19.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.19.4 BY END USER, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.20.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.20.4 BY END USER, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.21.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.21.4 BY END USER, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.22.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.22.4 BY END USER, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.23.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.23.4 BY END USER, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.24.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.24.4 BY END USER, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.25.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.25.4 BY END USER, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.26.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.26.4 BY END USER, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.27.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.27.4 BY END USER, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.28.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.28.4 BY END USER, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.29.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.29.4 BY END USER, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.30.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7.30.4 BY END USER, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Serotonin Antagonists
Dopamine Antagonists
Antihistamines
Glucocorticoids
Neurokinin-1 Antagonists

Healthcare By Administration Route (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Rectal

Healthcare By Therapeutic Area (USD Billion, 2025-2035)

Nausea
Vomiting
Chemotherapy-Induced Nausea
Post-Operative Nausea
Motion Sickness

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Home Care
Specialty Clinics
Ambulatory Surgical Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓